Fate Therapeutics, Inc. (FATE)
$
1.16
+0.05 (4.31%)
Key metrics
Financial statements
Free cash flow per share
-0.9700
Market cap
128 Million
Price to sales ratio
17.9343
Debt to equity
0.3386
Current ratio
7.8706
Income quality
0.7083
Average inventory
0
ROE
-0.5663
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing programmed cellular immunotherapies for cancer and immune disorders globally, recently reported a net loss of -$186,262,000.00 indicating challenges in its operations. Despite these challenges, the gross profit stands at $13,631,000.00 highlighting the company's profitability from core operations. The weighted average number of shares outstanding is 113,685,177.00 emphasizing the company's active shareholder base. Furthermore, the total costs and expenses for the company are $223,907,000.00 reflecting its overall spending and investment in research and development. The company reported an income before tax of -$186,262,000.00 showcasing its pre-tax profitability amid ongoing investment in promising therapeutic programs. With a market capitalization of $133,774,458.00 Fate Therapeutics is classified as a small-cap player, highlighting its position within the biopharmaceutical sector. The stock is affordable at $0.96 making it suitable for budget-conscious investors who are looking to invest in innovative companies. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape with its advanced NK- and T-cell immuno-oncology programs, which include FT516, FT596, FT538, FT576, FT819, FT536, and FT500. The stock has a high average trading volume of 2,101,680.00 indicating strong liquidity, which is appealing for potential investors. Additionally, the company belongs to the Healthcare sector, driving innovation and growth through its strategic collaborations and advanced research initiatives, including partnerships with Ono Pharmaceutical Co. Ltd., Juno Therapeutics, Inc., and Janssen Biotech, Inc.
Is Fate Therapeutics, Inc. (FATE) a good investment?
Investing in Fate Therapeutics, Inc. (FATE) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bullish outlook. Always conduct your own research before investing.
What is Fate Therapeutics, Inc. (FATE)'s stock forecast?
Analysts predict Fate Therapeutics, Inc. stock to fluctuate between $0.66 (low) and $2.07 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Fate Therapeutics, Inc.'s market capitalization?
As of 2025-12-12, Fate Therapeutics, Inc.'s market cap is $133,774,458, based on 115,322,809 outstanding shares.
How does Fate Therapeutics, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Fate Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Fate Therapeutics, Inc. (FATE) stock?
To buy Fate Therapeutics, Inc. (FATE) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for FATE. Place an order (Market, Limit, etc.).
What is the best time to invest in Fate Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Fate Therapeutics, Inc. perform in the last earnings report?
Revenue: $13,631,000 | EPS: -$1.64 | Growth: -0%.
Where can I find Fate Therapeutics, Inc.'s investor relations reports?
Visit https://www.fatetherapeutics.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Fate Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Fate Therapeutics, Inc. stock?
All-time high: $97.43 (2021-08-10) | All-time low: $0.66 (2025-04-04).
What are the key trends affecting Fate Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
Fate Therapeutics (FATE) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.4 per share a year ago.
globenewswire.com
Authorization Received from UK and EU Authorities to Activate ex-US Clinical Trial Sites Supporting the Ongoing Patient Enrollment of FT819, an Off-the-Shelf CD19-targeted CAR T-cell Product Candidate that Utilizes Less-intensive or No Conditioning, Enabling Broad Patient Accessibility
zacks.com
Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zacks.com
Relay, Fate and Verastem advance promising cancer therapies, strengthening their pipelines in a rapidly evolving oncology market.
zacks.com
Fate Therapeutics (FATE) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to a loss of $0.33 per share a year ago.
zacks.com
Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock?
zacks.com
Pfizer, Novartis and Fate Therapeutics are making bold oncology moves as demand surges for next-gen cancer therapies.
globenewswire.com
SAN DIEGO, May 30, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies to patients, today announced the appointment of Matthew Abernethy, M.B.A., to its Board of Directors effective as of May 29, 2025. Mr. Abernethy brings to the Company over 15 years' experience in corporate finance and investor relations in the biotech and medical device industry. In addition, the Company announced that Timothy P. Coughlin stepped down from the Board of Directors, effective concurrently with Mr. Abernethy's appointment.
zacks.com
FATE incurs a narrower-than-expected loss in the first quarter. The company's innovative pipeline remains in focus.
zacks.com
Fate Therapeutics (FATE) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.47 per share a year ago.
See all news
